Company: CERO
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001213900-25-011071
Chunk: 175

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-07
Form: 424B3
Chunk 175
---
 median survival of ~14.7 months. The prognosis for patients who are refractory
to or relapse after frontline azacitidine venetoclax is dismal with median overall survival of 2.4 months, making this an area of
high unmet need. Such patients who do not respond to frontline therapy with azacitidine or venetoclax, and the subset who do not respond
to targeted therapies, e.g., IDH1/2 inhibitors, are candidates for investigational trials. To date, there are no approved cell therapeutic
approaches to treat AML.

Ovarian Cancer

The American Cancer Society
estimates for ovarian cancer in the United States for 2024 are:

| ● | About                                                        
 19,680 women will receive a new diagnosis of ovarian cancer. |

| ● | About                                      
 12,740 women will die from ovarian cancer. |

Ovarian cancer is one of
the leading causes of cancer deaths among women. A woman’s risk of getting ovarian cancer during her lifetime is about 1 in 87.
Her lifetime chance of dying from ovarian cancer is about 1 in 130. (These statistics don’t count low malignant potential ovarian
tumors.) This cancer mainly develops in older women. About half of the women who are diagnosed with ovarian cancer are 63 years or older.
It is more common in White women than Black women.

<div align='center'>103</div>

Non-Small Cell Lung Cancer

Most lung cancer statistics
include both small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). In general, about 10% to 15% of all lung cancers are
SCLC, and about 80% to 85% are NSCLC. Lung cancer (both small cell and non-small cell) is the second most common cancer in both men and
women in the United States (not counting skin cancer).

The American Cancer Society’s
estimates for lung cancer in the US for 2024 are:

| ● | About                                                                  
 234,580 new cases of lung cancer (116,310 in men and 118,270 in women) |

| ● | About                                                               
 125,070 deaths from lung cancer (65,790 in men and 59,280 in women) |

Lung cancer mainly occurs
in older people. Most people diagnosed with lung cancer are 65 or older; a very small number of people diagnosed are younger than